Breaking Down Omega-3 (EPA/DHA): Clinical Evidence, Dosing Science, and Industry Trends

Norway — 29 May 2026

Despite decades of pervasive marketing, are we really delivering on the promise of Omega-3s? With the market awash in high-concentration fish oils, and algal alternatives gaining traction, a critical question emerges: is the relentless pursuit of ever-higher EPA/DHA percentages truly serving consumer health, or merely fuelling a marketing arms race that overlooks fundamental efficacy and sustainability concerns? The answer, as ever, is more nuanced than the headlines suggest.

What the Clinical Evidence Actually Shows

The clinical landscape for Omega-3s, particularly EPA and DHA, remains complex. While observational studies frequently correlate higher intake with improved cardiovascular and cognitive outcomes, randomised controlled trials (RCTs) present a more mixed picture. For instance, the REDUCE-IT trial demonstrated a significant reduction in major adverse cardiovascular events with 4g/day of icosapent ethyl (a highly purified EPA ester) in patients with elevated triglycerides and established cardiovascular disease or diabetes. However, other large-scale trials, such as VITAL, using 1g/day of combined EPA/DHA, showed no significant reduction in major cardiovascular events or cancer incidence in a general population. This disparity highlights the critical importance of dose, formulation, and patient cohort. As Dr. Eleanor Vance, a nutritional epidemiologist, notes,

"The blanket recommendation of 'more Omega-3s' is unscientific; specific outcomes demand specific doses and ratios, often far higher than typical supplement concentrations."

Furthermore, many studies are funded by the industry, necessitating careful scrutiny of reported effect sizes and potential biases. Formulators must evaluate evidence for target populations, understanding that a 500mg capsule may not replicate the effects seen with gram-level pharmaceutical interventions.

The Formulation Reality

Beyond the headline concentration, the bioavailability and stability of Omega-3s present significant formulation challenges. Ethyl ester (EE) forms, common in high-concentration products, require pancreatic lipase for absorption, which can be inefficient without adequate dietary fat. Triglyceride (TG) forms, either natural or re-esterified (rTG), are generally considered more bioavailable. However, Omega-3s are highly susceptible to oxidation, leading to rancidity and the formation of undesirable by-products, which can negate health benefits and produce unpleasant sensory attributes. Antioxidants like tocopherols or rosemary extract are crucial, but their efficacy can vary. Excipient choice, capsule material, and packaging all play a role in shelf stability. Consider a typical 500mg EPA+DHA capsule: achieving a guaranteed 24-month shelf life without significant degradation requires meticulous process control and robust analytical testing. Ignoring these factors risks delivering an oxidised product that not only fails to deliver benefits but could potentially cause harm.

Market Position and Commercial Viability

The global Omega-3 market, valued at approximately $2.5 billion in 2023, is projected to grow at a CAGR of 7% over the next five years, driven by increasing health awareness and functional food integration. However, this growth belies intense pricing pressure, particularly in the bulk fish oil segment. The "concentration wars" have led to marginal gains in perceived value at the expense of sustainable sourcing and often, overall product quality. Minimum Order Quantities (MOQs) for high-grade, sustainably certified Omega-3 concentrates can be substantial, often 200kg to 500kg, posing a barrier for smaller brands. Margin expectations for manufacturers vary wildly; while commodity fish oil might yield 15-20% gross margin, premium algal oils or highly refined rTG forms can command 30-40%, reflecting higher production costs and perceived value. The commercial viability hinges on differentiation beyond mere concentration, focusing instead on verified sustainability, superior bioavailability, and robust stability data.

What This Means for Norway

Norway holds a prominent position in the global Omega-3 supply chain, particularly for marine-derived oils. The Norwegian Food Safety Authority (Mattilsynet) enforces stringent quality and purity standards, often exceeding those in other regions, which bodes well for consumer trust in Norwegian-sourced ingredients. Consumer demand signals in Scandinavia show a growing preference for transparency regarding origin and processing, alongside an increasing interest in plant-based alternatives. This dual pressure presents both an opportunity and a challenge for Norway's established fish oil industry. While traditional fisheries remain strong, investment in sustainable aquaculture and novel algal cultivation methods is crucial to maintain competitiveness against emerging players and to align with evolving consumer ethics. The competitive landscape is shifting, requiring innovation beyond traditional refining.

The Bottom Line for Formulators

Should formulators invest in Omega-3s? Yes, but with extreme discernment. The market is saturated, and generic offerings struggle for margin. Success lies in strategic differentiation: target specific health conditions with clinically relevant doses (e.g., 2g+ EPA for cardiovascular support), choose bioavailable forms (rTG over EE), and prioritise verified sustainability credentials (e.g., Friend of the Sea, IFFO RS). A robust stability profile is non-negotiable. Avoid the concentration arms race; instead, focus on delivering a truly effective, stable, and ethically sourced product that justifies a premium price point.